LX2761

LX2761 is an orally administered, locally acting small molecule inhibitor of sodium-glucose cotransporter 1 (SGLT1) developed for the treatment of diabetes. It is designed to act primarily in the gastrointestinal tract, minimizing systemic absorption and effects. LX2761 delays intestinal glucose absorption, thereby lowering postprandial and fasting blood glucose levels, as well as hemoglobin A1C, while increasing plasma levels of glucagon-like peptide-1 (GLP-1). In preclinical models, LX2761 improved glycemic control and showed a dose-dependent reduction in glucose excursions, as well as synergistic increases in GLP-1 when combined with dipeptidyl peptidase-4 inhibitors such as sitagliptin. The most commonly reported side effect in both animal and early clinical studies is diarrhea, which is generally dose-dependent and may decrease in frequency with dose adjustment or gradual escalation. The drug is being developed by Lexicon Pharmaceuticals and, as of the most recent updates, remains in phase 1 clinical trials for type 2 diabetes mellitus[1][2][3][4][5][9].